{Company} Site Feasibility Survey

{Date}

Project Background/Business Objectives

- {Company} will be placing one Phase {X} study with {number} subjects and 2 Phase {X} studies with {number} subjects and {number} subjects, respectively, in late {year}.
- {Company} was interested in conducting a site feasibility survey among investigators in countries where competitors developing {medical condition} treatments have little or no presence.

Survey Methodology

- Base survey instrument initially developed by CenterWatch. This base survey instrument was then customized with {Company's} input to produce the final questionnaire.
- Survey conducted online from {Month-Month / Year}:
- Initial response to the survey was approx. {X%}. However, an early screening of the responses identified less viable investigators than originally anticipated. CenterWatch expanded the country list, and with {Company's} approval, expanded the search to the US.
- Survey emailed to {number} investigators and study coordinators worldwide.
- {Number} investigative site contacts worldwide identified. Among those worldwide investigative sites, {number} investigative site contacts are located in countries where little or no competitive presence exists.
- Among those sites where a competitive presence exists, only {number} currently have ongoing similar [medical condition} studies.

Countries

Countries highlighted in yellow indicate little or no competitive presence

Country	
United States	56.8%
Germany	5.6%
India	3.5%
Russia	3.2%
Canada	2.9%
Israel	2.7%
Brazil	2.4%
Ukraine	2.1%
Australia	1.9%
United Kingdom	1.9%
France	1.9%
Latvia	1.3%
Belgium	1.3%
New Zealand	1.1%
Finland	.8%

Country	
South Africa	.8%
Spain	.8%
Romania	.8%
Argentina	.8%
Austria	.5%
China	.5%
Denmark	.5%
Greece	.5%
Hong Kong	.5%
Hungary	.5%
Italy	.5%
Mexico	.5%
Switzerland	.5%
Serbia	.5%
Bulgaria	.3%

n=374

Average Number of Patients Enrolled per [Medical Condition} Trial

	Average Number of Patients Per {MC} Trial	Average Enrollment Period Per {MC}Trial
TOTAL Sample (n=374)	10.5 (mean) 4.0 (median)	10.6 months (mean) 12 months (median)
Countries with little/no competitive presence (n=87)	21 (mean) 4.0 (median)	13.4 months (mean) 12 months (median)

{Data on specific survey question}



# of Patients Enrolled	Enrollment Period
6.5 (mean) 5.0 (median)	9.2 months (mean) 8 months (median)

# of Patients Enrolled	Enrollment Period
7.5 (mean) 4.5 (median)	12.8 months (mean) 10 months (median)

Average Turnaround Time:

Contract Negotiation to Budget Approval with Sponsor

	Turnaround Time
Total Sample (n=374)	4.6 weeks (mean) 3 weeks (median) Range: 1 day to 26 weeks
Countries with little to no competitive presence (n=87)	6.3 weeks (mean) 4.3 weeks (median) Range: 1 week to 26 weeks

Average Turnaround Time:

Protocol Submission to Regulatory Approval

	Turnaround Time
Total Sample (n=374)	1.0 months (mean) .7 months (median) Range: 1 day to 6 months
Countries with little to no competitive presence (n=87)	1.7 months (mean) 1.5 months (median) Range: 10 days to 9 months

Capability of Using a Central Ethics Committee or Central IRB



Use of EDC Technologies

Countries with little/no competitive presence



n=87

TOTAL Sample



n=374

Technology Platforms Used